In this study, the biomarkers of liver injury (such as ALT and AST) and lipid factors (including HDL-C and LDL-C) were evaluated to assess the effects of various treatments on NAFLD. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.